A Phase 2B Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of BMS-986036 (PEG-FGF21) in Adults With Nonalcoholic Steatohepatitis (NASH) and Compensated Liver Cirrhosis
Latest Information Update: 28 Dec 2023
At a glance
- Drugs Pegbelfermin (Primary)
- Indications Hepatic fibrosis; Liver cirrhosis; Non-alcoholic steatohepatitis
- Focus Therapeutic Use
- Acronyms FALCON 2
- Sponsors Bristol-Myers Squibb
- 14 Nov 2023 Results of post-hoc exploratory analysis comparing FibroNest's continuous scores with NASH-CRN categorical stages in patients with NASH, presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases.
- 14 Nov 2023 Results obtaining biopsy slide from NCT03486899and NCT03486912, investigating the possibility to overcome this limitation using multi parametric measurements like Somalogic (a biomarker) and qFibrosis (AI histology), presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases
- 08 Mar 2022 Status changed from active, no longer recruiting to completed.